Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Mattsson

Showing results (171-180 of 258) with videos related to

Pageof 26
Sort By:
European Journal of Haematology|March 3, 2020
Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantationRam Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, et al.
Hematology/Oncology and Stem Cell Therapy|March 29, 2021
Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell TransplantationRam Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, et al.
Plos One|May 16, 2023
A longitudinal multidimensional rehabilitation program for patients undergoing allogeneic blood and marrow transplantation (CaRE-4-alloBMT): Protocol for a phase II feasibility pilot randomized controlled trialSamantha Tam, Rajat Kumar, Paty Lopez, et al.
European Journal of Haematology|May 29, 2025
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD ProphylaxisAhmed Alnughmush, Ruah Alyamany, Mats Remberger, et al.
Clinical Hematology International|October 1, 2021
Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-<i>versus</i>-Host Disease ProphylaxisMaria Queralt Salas, Arjun Datt Law, Wilson Lam, et al.
British Journal of Haematology|September 18, 2025
Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxisRuah Alyamany, Ahmed Alnughmush, Mats Remberger, et al.
British Journal of Haematology|August 27, 2025
A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantationNihar Desai, Sergio Rodriguez-Rodriguez, Eshrak Al-Shaibani, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 6, 2021
Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant PatientsEshrak Al-Shaibani, Rhida Bautista, Jeffrey H Lipton, et al.
European Journal of Haematology|December 14, 2025
Eltrombopag in Treating Post-Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug TaperingRawan Al-Omari, Ram Vasudevan Nampoothiri, Ali Sakhdari, et al.
European Journal of Haematology|May 8, 2025
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap NeoplasmsNihar Desai, Sergio Rodriguez-Rodriguez, Carol Chen, et al.
Pageof 26

Showing results (171-180 of 258) with videos related to

Sort By:
Pageof 26
European Journal of Haematology|March 3, 2020
Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantationRam Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, et al.
Hematology/Oncology and Stem Cell Therapy|March 29, 2021
Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell TransplantationRam Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, et al.
Plos One|May 16, 2023
A longitudinal multidimensional rehabilitation program for patients undergoing allogeneic blood and marrow transplantation (CaRE-4-alloBMT): Protocol for a phase II feasibility pilot randomized controlled trialSamantha Tam, Rajat Kumar, Paty Lopez, et al.
European Journal of Haematology|May 29, 2025
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD ProphylaxisAhmed Alnughmush, Ruah Alyamany, Mats Remberger, et al.
Clinical Hematology International|October 1, 2021
Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-<i>versus</i>-Host Disease ProphylaxisMaria Queralt Salas, Arjun Datt Law, Wilson Lam, et al.
British Journal of Haematology|September 18, 2025
Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxisRuah Alyamany, Ahmed Alnughmush, Mats Remberger, et al.
British Journal of Haematology|August 27, 2025
A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantationNihar Desai, Sergio Rodriguez-Rodriguez, Eshrak Al-Shaibani, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 6, 2021
Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant PatientsEshrak Al-Shaibani, Rhida Bautista, Jeffrey H Lipton, et al.
European Journal of Haematology|December 14, 2025
Eltrombopag in Treating Post-Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug TaperingRawan Al-Omari, Ram Vasudevan Nampoothiri, Ali Sakhdari, et al.
European Journal of Haematology|May 8, 2025
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap NeoplasmsNihar Desai, Sergio Rodriguez-Rodriguez, Carol Chen, et al.
Pageof 26